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Abstract
Activation of glutamate receptors has been proposed as a key factor in the induction of ischemic tolerance. We used organotypic rat
hippocampal slices exposed to 30 min oxygen–glucose deprivation (OGD) to evaluate postischemic pyramidal cell death in the CA1
subregion. In this model, 10 min exposure to OGD 24 h before the exposure to toxic OGD was not lethal and reduced the subsequent
OGD neurotoxicity by  53% (ischemic preconditioning). Similarly, a 30 min exposure to the group I mGlu receptor agonist DHPG
(10 lM) significantly reduced OGD neurotoxicity 24 h later (pharmacological preconditioning). Ischemic tolerance did not develop
when either the selective mGlu1 antagonists LY367385 and 3-MATIDA or the AMPA ⁄ KA antagonist CNQX were present in the
incubation medium during exposure to sublethal OGD. Neither the NMDA antagonist MK801 nor the mGlu5 antagonist MPEP
affected the preconditioning process. On the other hand, pharmacological preconditioning was prevented not only by LY367385 or
CNQX, but also by MPEP. In preconditioned slices, the toxic responses to AMPA or NMDA were reduced. The neurotoxicty of
100 lM DHPG in slices simultaneously exposed to a mild (20 min) OGD was differentially altered in the two preconditioning
paradigms. After ischemic preconditioning, DHPG neurotoxicity was reduced in a manner that was sensitive to LY367385 but not to
MPEP, whereas after pharmacological preconditioning it was enhanced in a manner that was sensitive to MPEP but not to
LY367385. Our results show that mGlu1 and mGlu5 receptors are differentially involved in the induction and expression of ischemic
tolerance following two diverse preconditioning stimuli.
Introduction
Exposure of brain slices or isolated neurons in culture to a short
sublethal period of oxygen and glucose deprivation (OGD) has been
shown to reduce cell death induced by a subsequent more prolonged
and otherwise lethal hypoxic or ischemic insult (Schurr et al., 1986;
Grabb & Choi, 1999). The molecular mechanisms leading to an
increased neuronal resistance to ischemic injury (a phenomenon
known as ischemic preconditioning or ischemic tolerance) are still not
clearly understood and a number of possible induction pathways,
including activation of glutamate receptors and changes in the
concentration of intracellular free Ca2+, have been proposed (Dirnagl
et al., 2003; Bickler & Fahlman, 2004; Gidday, 2006). Recently, it has
been demonstrated that brief activation of group I metabotropic
glutamate (mGlu) receptors (consisting of mGlu1 and mGlu5 receptor
subtypes) with the selective agonist (S)-3,5-dihydroxyphenylglycine
(DHPG) reduces NMDA-mediated Ca2+ inflow and the resulting cell
death, suggesting that activation of these mGlu subtypes may
contribute to the induction of tolerance towards excitotoxic events
(Blaabjerg et al., 2003; Baskys et al., 2005).
Both mGlu1 and mGlu5 receptors are present in the hippo-
campus: mGlu5 is the predominant receptor expressed on CA1
pyramidal cells (Baude et al., 1993; Romano et al., 1995) whereas
the mGlu1 subtype in CA1 has been detected mostly in GABAergic
interneurons of the stratum oriens (Shigemoto et al., 1992; Berthele
et al., 1998; Ferraguti et al., 1998). Activation of mGlu1 receptors
has been shown to regulate CA1 pyramidal cell excitability by
modulating GABAergic transmission (Gereau & Conn, 1995;
Fitzsimonds & Dichter, 1996) and ⁄ or by directly acting on
principal neurons (Mannaioni et al., 2001). Previous studies from
our laboratory have shown that mGlu1 but not mGlu5 receptor
antagonists significantly reduce postischemic neuronal damage in
both in vitro and in vivo models of cerebral ischemia (Pellegrini-
Giampietro et al., 1999a,b; Cozzi et al., 2002; Meli et al., 2002),
suggesting that activation of this particular receptor subtype
significantly contributes to the events leading to postischemic
neurodegeneration. Along this line, we also showed that DHPG
exacerbated neuronal injury in mixed cortical cultures and organo-
typic hippocampal slices exposed to OGD (Pellegrini-Giampietro
et al., 1999a).
With the aim of investigating the role of group I mGlu receptors in
both the induction and the expression of ischemic tolerance, we used
organotypic hippocampal slices exposed to either ischemic or
pharmacological preconditioning paradigms, and a number of glu-
tamate receptor agonists and antagonists. In particular, we examined
whether activation of mGlu1 and ⁄ or mGlu5 receptors was necessary
to initiate the process leading to ischemic tolerance and whether the
expression of ischemic tolerance was associated with changes in
glutamate receptor-mediated neurotoxicity.
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Materials and methods
Materials
The glutamate receptor agents DHPG, (S)-(+)-alpha-amino-4-carboxy-
2-methylbenzene-acetic acid (LY367385), 3-methyl-aminothiophene
dicarboxylic acid (3-MATIDA), 2-methyl-6-(phenyl-ethynyl)-pyridine
(MPEP), (+)MK801 maleate (MK801) and 6-cyano-7-nitro-quinox-
aline-2,3-dione (CNQX) were purchased from Tocris Cookson
(Bristol, UK). Tissue culture reagents were obtained from Gibco-
BRL (San Giuliano Milanese, MI, Italy) and ICN Pharmaceuticals
(Opera, MI, Italy). Propidium iodide (PI) was purchased from
Molecular Probes (Leiden, the Netherlands). If not otherwise declared,
all cell culture media were purchased from MP Biomedicals (Irvine,
CA, USA).
Preparation of organotypic cultures
Animal use was approved by the Ethical Committee for Animal Care,
Department of Pharmacology, University of Florence. All experiments
conformed to Italian and international guidelines on the ethical use of
animals. The number of animals was kept to the minimum level
necessary for this study. Organotypic slice cultures of the hippocam-
pus were prepared as previously described in detail (Pellegrini-
Giampietro et al., 1999a). Briefly: neonatal pups (8–10 days old) of
Wistar rats were decapitated and the hippocampi were dissected free
from the forebrain and transversely sliced (400 lm) on a McIlwain
tissue chopper. Slices were placed in Hanks’s balanced salt solution
(supplemented with 5 mg ⁄mL glucose and 3.75 lg ⁄mL amphoteri-
cin B) at 4 C. The slices were then transferred onto 30-mm-diameter
membrane inserts (Millicell-CM; Millipore, Italy) and placed into six-
well culture trays with 1.2 mL of slice culture medium per well. The
slice culture medium consisted of: Eagle’s minimal essential medium,
50%; Hanks’s balanced salt solution, 25%; heat-inactivated horse
serum, 25%; l-glutamine, 2 mm; glucose, 5 mg ⁄mL; and amphoteri-
cine B, 3.75 lg ⁄mL. The cultures were maintained at 37 C in an
atmosphere of humidified air and 5% CO2. The slice culture medium
was changed twice a week. Slices were kept in culture for 12–14 days
before experiments. At the end of this culture period and prior to the
Fig. 1. Ischemic and pharmacological preconditioning in organotypic hippocampal slices. Cultured slices were exposed to 30 min OGD and 48 h later incubated
with PI for fluorescence detection of its optical density (OD). (CRL) Hippocampal slice under normoxic and drug-free conditions (background PI fluorescence).
(OGD) Hippocampal slice exposed to 30 min OGD, displaying more intense PI labelling in the CA1 region than in the CA3 and dentate gyrus. (IP) Hippocampal
slice exposed to ischemic preconditioning (IP) 24 h prior to OGD, displaying reduced CA1 PI labelling as compared to OGD alone. (PP) Hippocampal slice exposed
to pharmacological preconditioning (PP: DHPG 10 lm, 30 min) 24 h prior to OGD, displaying a similar reduction in CA1 PI labelling.
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experiments all slices were screened for viability by incubating them
for 30 min with PI (5 lg ⁄mL); slices displaying signs of neuro-
degeneration were discarded from the study.
OGD in rat hippocampal slices
Organotypic hippocampal slice cultures were exposed to OGD as
previously reported in detail (Pellegrini-Giampietro et al., 1999a).
Briefly, the slices were subjected to OGD by exposing them to a
serum- and glucose-free medium saturated with 95% N2 and 5% CO2
at 37 C in a gassed incubator equipped with an oxygen gas controller
(BioSpherix, New York, USA). Following 30 min of OGD the
cultures were transferred to oxygenated serum-free medium (Eagle’s
minimal essential medium, 75%; Hank’s balanced salt solution, 25%;
l-glutamine, 2 mm; and amphotericin B, 3.75 lg ⁄mL) containing
5 mg ⁄mL glucose and returned to the incubator under normoxic
conditions until neuronal injury was evaluated 48 h later. The potential
toxicity of amphotericin B was tested in a series of experiments
carried out in the absence and in the presence of the drug; these
produced virtually identical results.
Assessment of neuronal injury
Cell injury was assessed using the fluorescent dye PI, a highly
polar compound which is normally excluded from cells with an
intact membrane. When the membrane is damaged, PI enters the
cells and upon binding to exposed DNA becomes highly fluores-
cent. PI (5 lg ⁄mL) was added to the medium at the end of the 48-h
post-OGD recovery period. Thirty minutes later, fluorescence was
viewed using an inverted fluorescence microscope (Olympus IX-50;
Solent Scientific, Segensworth, UK) equipped with a xenon-arc
lamp, a low-power objective (4·) and a rhodamine filter. Images
were digitized using a video image obtained by a CCD camera
(Diagnostic Instruments Inc., Sterling Heights, MI, USA) controlled
by software (InCyt Im1TM; Intracellular Imaging Inc., Cincinnati,
OH, USA) and subsequently analysed using the Image-Pro Plus
morphometric analysis software (Media Cybernetics, Silver Spring,
MD, USA). In order to quantify cell death, the CA1 hippocampal
subfield was identified and encompassed in a frame using the
drawing function in the image software (ImageJ; NIH, Bethesda,
Fig. 2. Ischemic (IP) and pharmacological (PP) preconditioning attenuated
CA1 damage produced by OGD in organotypic hippocampal slices. OGD was
applied for 30 min and 48 h later CA1 damage was assessed by measuring the
intensity of PI fluorescence. Data are expressed as percentages of maximal
neuronal death, as measured following the application of 10 mm glutamate for
48 h. CA1 damage was significantly reduced when slices were pre-exposed to a
brief (10 min) OGD (IP) or to 10 lm DHPG for 30 min (PP) 24 h before the
toxic challenge of 30 min OGD. Bars represent the mean ± SEM of n ‡ 6
experiments run in quadruplicate. *P < 0.05 and **P < 0.01 vs. OGD.
Table 1. Effects of glutamate receptor antagonists on the induction of
ischemic preconditioning in rat organotypic hippocampal slice cultures
CA1 PI fluorescence (%)
Basal 54 ± 11 (22)
30 min OGD 145 ± 20 (62)
Glutamate (10 mm) 232 ± 10** (100)
Ischemic preconditioning (IP) 97 ± 20* (41)
IP + 100 lm LY367385 169 ± 22 (73)
IP + 10 lm MPEP 75 ± 16* (31)
IP + 100 lm MK801 87 ± 20* (36)
IP + 10 lm CNQX 144 ± 4 (60)
Data are presented as means ± SEM, with percentages of glutamate-induced
neuronal injury in parentheses. OGD was applied for 30 min and, 48 h later,
neuronal damage was assessed by measuring the intensity of PI fluorescence.
Maximal damage was achieved by exposing the slices to 10 mm glutamate for
48 h. Ischemic preconditioning (IP) was performed by exposing the slices to a
sublethal period (10 min) of OGD 24 h before the toxic challenge of 30 min
OGD. Drugs were added to the incubation medium 15 min prior to and during
IP, but not during the subsequent recovery period. Data are expressed as CA1
fluorescence 48 h after the exposure to glutamate or OGD. OGD-induced
neuronal death was significantly reduced by IP. LY367385 (100 lm) and
CNQX (10 lm) but not MPEP (10 lm) nor MK801 (100 lm) prevented IP.
Values represent the mean ± SEM of n ‡ 6 experiments. *P < 0.05 and
**P < 0.01 vs. 30 min OGD.
Table 2. Effects of glutamate receptor antagonists on the induction of
pharmacological preconditioning with DHPG in rat organotypic hippocampal
slice cultures
CA1 PI fluorescence (%)
Basal 56 ± 11 (23)
30 min OGD 162 ± 22 (71)
Glutamate (10 mm) 241 ± 1** (100)
DHPG 10 lm (PP) 107 ± 13* (44)
PP + 100 lm LY367385 180 ± 7 (74)
PP + 10 lm MPEP 161 ± 11 (67)
PP + 100 lm MK801 66 ± 15* (28)
PP + 10 lm CNQX 194 ± 13 (80)
Data are presented as means ± SEM, with percentages of glutamate-induced
neuronal injury in parentheses. OGD was applied for 30 min and, 48 h later,
neuronal damage was assessed by measuring the intensity of PI fluorescence.
Maximal damage was achieved by exposing the slices to 10 mm glutamate for
48 h. Pharmacological preconditioning (PP) was performed by exposing the
slices to 10 lm DHPG for 30 min 24 h before the toxic challenge of 30 min
OGD. Drugs were added to the incubation medium 15 min prior and during PP,
but not during the subsequent recovery period. Data are expressed as CA1
fluorescence 48 h after the exposure to glutamate or OGD. OGD-induced
neuronal death was significantly reduced by PP. LY367385 (100 lm),
MPEP (10 lm) and CNQX (10 lm), but not MK801 (100 lm) prevented PP.
Values represent the mean ± SEM of n ‡ 6 experiments. *P < 0.05 and
**P < 0.01 vs. 30 min OGD.
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MD, USA) and the optical density of PI fluorescence was detected.
There was a linear correlation between CA1 PI fluorescence and the
number of injured CA1 pyramidal cells as detected by morpholo-
gical criteria (see Pellegrini-Giampietro et al., 1999a).
Experimental design
Typical examples of slice cultures and time settings for precondition-
ing experiments are given in Fig. 1. Paradigms for control and OGD
experiments are shown in the upper row and preconditioning protocols
are shown in the lower row. For ischemic preconditioning experi-
ments, slices were pre-exposed to a sublethal period of OGD (10 min)
and then, 24 h later, to 30 min OGD (Fig. 1, IP). For pharmacological
preconditioning experiments with DHPG (Fig. 1, PP), slices were pre-
exposed to the group I mGlu receptor agonist DHPG (10 lm) for
30 min and then, 24 h later, to 30 min OGD.
Statistical analysis
Data are given as mean ± SEM of n experiments. Statistical signifi-
cance of differences was analysed using anova followed by Tukey’s
w-test. A P-value of 0.05 was considered significant. All statistical
calculations were performed using GraphPad Prism 4.00 for Windows
(GraphPad Software, San Diego, CA, USA).
Results
Ischemic and pharmacological preconditioning
In accord with previous observations (Pellegrini-Giampietro et al.,
1999a,b; Meli et al., 2002), exposure of hippocampal slices to OGD for
30 min caused an increase in PI fluorescence in the CA1 subregion that
was 65% of the fluorescence intensity obtained by exposing the slices
to 10 mm glutamate for 48 h (100% neuronal damage). Figures 1 and 2
and Table 1 show that exposure to a sublethal period of OGD (10 min)
reduced the toxic effects of a subsequent (24 h later) 30 min exposure to
OGD; this ischemic preconditioning paradigm significantly reduced PI
fluorescence by 53 ± 5%. Interestingly, a similar significant reduction
(by 49 ± 5%) inCA1 damage induced by 30 minOGDwas observed by
pre-exposing the preparation to DHPG (10 lm) for 30 min 24 h before
the toxic challenge (pharmacological preconditioning; Figs 1 and 2,
Table 2). No reduction was observed when pre-exposure of slices to the
same paradigm (10 lm DHPG for 30 min) was carried out 2 h before
exposure to 30 min OGD. Larger DHPG concentrations (100 lm) did
not induce pharmacological preconditioning but rather exacerbated the
subsequent OGD-induced cell death (data not shown).
Effects of glutamate receptor antagonists on the induction
of ischemic or pharmacological preconditioning
To evaluate whether activation of ionotropic or group I metabotropic
glutamate receptors is involved in the development of ischemic or
pharmacological preconditioning, a number of selective antagonists
were used. Tables 1 and 2 show that the AMPA ⁄ kainate receptor
antagonist CNQX (10 lm) prevented the development of tolerance to
OGD when present in the incubation medium during pre-exposure of
slices to both sublethal OGD (ischemic preconditioning) and to 10 lm
DHPG (pharmacological preconditioning). In contrast, the NMDA
antagonist MK801 (100 lm) did not modify the induction of tolerance
to OGD. Ischemic preconditioning was also prevented by the selective
mGlu1 receptor antagonists LY367385 (10–100 lm) and 3-MATIDA
(10–100 lm) (Fig. 3A, Table 1) but not by the mGlu5 receptor
antagonist MPEP (10 lm, Table 1). Interestingly, the tolerance to
OGD induced by DHPG could be completely prevented by either
LY367385 (10–100 lm) or MPEP (10–50 lm Fig. 3B, Table 2),
suggesting that the mechanisms and processes of tolerance induction
are not identical in the two experimental paradigms used.
Fig. 3. Effects of group I mGlu receptor antagonists on the induction of
(A) ischemic and (B) pharmacological preconditioning (IP and PP, respect-
ively) in rat organotypic hippocampal slices. Experiments were carried out as
indicated in the legends to Tables 1 and 2. Data are expressed as percentages of
OGD-induced CA1 toxicity, as determined by the intensity of PI fluorescence
in this region. OGD toxicity was significantly reduced by (A) IP and (B) PP.
IP was significantly prevented by the mGlu1 receptor antagonists LY367385
(10–100 lm) and 3-MATIDA (10–100 lm), whereas PP was significantly
prevented by LY367385 (10–100 lm) and by the mGlu5 receptor antagonist
MPEP (10–50 lm). Bars represent the mean ± SEM of n ‡ 4 experiments run
in quadruplicate. *P < 0.05 vs. OGD.
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Preconditioning and glutamate receptor-mediated
neuronal death
In order to evaluate the mechanisms leading to tolerance towards the
OGD insult, we investigated the effects of ischemic or pharmacolo-
gical preconditioning on the subsequent neurotoxicity induced by
ionotropic and group I metabotropic glutamate receptor agonists.
Exposure of slices to AMPA (100 lm) or NMDA (300 lm) for
60 min produced a pattern of neurotoxicity, as observed 48 h later,
that was slightly more intense and less selective for CA1 than that
induced by 30 min OGD (Fig. 4). When we tested whether a 24-h pre-
exposure to preconditioning stimuli could affect AMPA or NMDA
toxicity, we observed that both the ischemic and the pharmacological
preconditioning paradigms reduced the neurotoxicity caused by
3–30 lm AMPA or 10–100 lm NMDA but were unable to attenuate
the injury induced by the highest concentrations of ionotropic
glutamate receptor agonists (Fig. 5A and B).
We have previously shown that 100 lm DHPG is not toxic by itself
but significantly aggravates CA1 injury when added to hippocampal
slices exposed to OGD (Pellegrini-Giampietro et al., 1999a). In order
to evaluate whether ischemic or pharmacological preconditioning
could affect mGlu1 and mGlu5 receptor sensitivities, we exposed
preconditioned slices to a protocol in which the agonist DHPG
(100 lm) enhanced the modest CA1 damage produced by a brief
period (20 min) of OGD (Figs 4, 6 and 7). In slices pre-exposed to
ischemic preconditioning (Fig. 6), the DHPG-triggered increase in
mild OGD neurotoxicity was markedly reduced (from 182 ± 24% vs.
mild OGD alone, to 120 ± 11%), in a manner that was completely
prevented by the mGlu1 receptor antagonist LY367385 (100 lm) but
not by the mGlu5 receptor antagonist MPEP (10 lm). In contrast, in
slices pre-exposed to pharmacological preconditioning (Fig. 7), the
increase in CA1 neuronal death induced by DHPG plus mild OGD
was remarkably increased (from 165 ± 13% vs. mild OGD alone, to
358 ± 68%). In this case, the selective mGlu5 antagonist MPEP
(10 lm), but not the mGlu1 antagonist LY367385 (100 lm), preven-
ted the increased neurotoxic response to DHPG in mild OGD.
Discussion
In models of cerebral preconditioning, stimuli that are harmful or
toxic to the brain can induce neuroprotection when administered for
brief periods or at low doses. In accord with results obtained in
other laboratories (for reviews see: Dirnagl et al., 2003; Gidday,
2006), we observed that a brief period (10 min) of sublethal OGD
in organotypic hippocampal slices increased neuronal survival after
Fig. 4. Excitotoxic injury in organotypic hippocampal slices. Slices were exposed to (A) 100 lm AMPA for 60 min, (B) 300 lm NMDA for 60 min, (C) mild
(20 min) OGD or (D) 100 lm DHPG + mild OGD, and 48 h later incubated with PI and observed under fluorescence optics. AMPA and NMDA produced striking
and nonselective injury in CA1, CA3 and in the dentate gyrus, whereas mild OGD induced a modest and selective CA1 damage that was clearly enhanced by the
addition of DHPG.
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a subsequent, more prolonged (30 min), and otherwise lethal OGD
insult. In other experiments, we observed that DHPG (10 lm), a
group I mGlu receptor agonist, applied to the slices for 30 min
24 h before the lethal OGD challenge, significantly attenuated CA1
injury, whereas a higher concentration (100 lm) of DHPG exacer-
bated the subsequent OGD-induced neuronal death. These observa-
tions suggest that activation of group I mGlu receptors is sufficient
to trigger mechanisms culminating in an increased resistance to
ischemic insults (ischemic tolerance). It has been previously
reported that it is possible to increase neuronal resistance to
ischemic insults by pre-exposing slices to glutamate (Schurr et al.,
2001), NMDA (Raval et al., 2003), adenosine A1 receptor agonists
(Lange-Asschenfeldt et al., 2004) or a period of moderate increase
in intracellular Ca2+ concentrations (Bickler & Fahlman, 2004).
Because group I mGlu receptors share with these other approaches
the ability to increase intracellular Ca2+ levels, the latter might
represent a common pathway able to lead to an increased neuronal
resistance to ischemic insults. Another possible mechanism that may
contribute to the group I mGlu receptor-mediated development of
ischemic tolerance is the rapid increase in excitability that has been
reported in hippocampal pyramidal cells exposed to relatively low
doses (10 lm) of DHPG (Young et al., 2004).
In cultured hippocampal slices, selective antagonists of NMDA,
AMPA or mGlu1 receptors significantly reduce CA1 injury when
added to the incubation medium during and after a 30-min OGD insult
(Pellegrini-Giampietro et al., 1999a,b). In the present study, we
evaluated the effects of glutamate receptor antagonists when added to
the medium during two different preconditioning procedures that were
performed 24 h before the lethal exposure to OGD. Interestingly,
AMPA or mGlu1 antagonists prevented the development of ischemic
tolerance but, to our surprise, even elevated concentrations of MK801
(10–100 lm) failed to do so. In contrast, other laboratories have
shown that NMDA receptor antagonists (including 10 lm MK801)
prevent the induction of ischemic tolerance (Raval et al., 2003). It has
also been shown that activation of group I mGlu receptors produces
Fig. 5. Ischemic (IP) and pharmacological (PP) preconditioning reduced the
toxicity induced by ionotropic glutamate receptor agonists in rat organotypic
hippocampal slices. Slices were exposed to (A) 1–100 lm AMPA or
(B) 3–300 lm NMDA for 60 min and 48 h later CA1 damage was assessed
by measuring the intensity of PI fluorescence. Data are expressed as percentages
of maximal (A) AMPA or (B) NMDA toxicity. The toxicity evoked by (A)
3–30 lm AMPA or (B) 10–100 lm NMDA was reduced when slices were
pre-exposed 24 h earlier to a brief (10 min) OGD (IP) or to 10 lm DHPG for
30 min (PP). Values represent the mean ± SEM of n ‡ 3 experiments run in
quadruplicate. *P < 0.05 vs. correspondent AMPA or NMDA concentration.
Fig. 6. Ischemic preconditioning (IP) reduced DHPG toxicity in rat organ-
otypic hippocampal slices. Slices were exposed to 100 lm DHPG, OGD or
DHPG + OGD for 20 min and 48 h later CA1 damage was assessed by
measuring the intensity of PI fluorescence. Data are expressed as percentages of
20 min OGD-induced neuronal death. The toxicity evoked by DHPG was
significantly reduced when slices were pre-exposed 24 h earlier to a brief
(10 min) OGD (IP). The mGlu1 receptor antagonist LY367385 (100 lm), but
not the mGlu5 receptor antagonist MPEP (10 lm), was able to prevent the
reduction induced by IP. Bars represent the mean ± SEM of n ‡ 4 experiments
run in quadruplicate. **P < 0.01 vs. OGD 20 min alone.
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rapid protection against NMDA-mediated neuronal death (Arnett
et al., 2004). The different time periods used for the precondi-
tioning procedures (10 vs. 15 min) or the different intervals used
before the exposure to the toxic stimuli may explain these apparent
discrepancies.
The use of selective mGlu1 and mGlu5 receptor antagonists
allowed us to differentiate the processes activated by either ischemic
or pharmacological preconditioning. Both MPEP, a selective mGlu5
antagonist (Gasparini et al., 1999), and LY367385, a selective
competitive mGlu1 antagonist (Kingston et al., 1999), significantly
reduced the preconditioning effects induced by DHPG (10 lm),
suggesting that activation of both mGlu1 and mGlu5 receptors was
necessary to induce ischemic tolerance in our model of pharmacolo-
gical preconditioning. On the other hand, the preconditioning effect
activated by a brief (10 min) OGD exposure was reduced by
LY367385 and by another mGlu1 receptor antagonists, 3-MATIDA
(Moroni et al., 2002), but not by the mGlu5 receptor antagonist MPEP,
indicating that under these conditions mGlu1 receptors contribute
more substantially than mGlu5 receptors to the induction of ischemic
tolerance. It is interesting to note that, under selected conditions,
mGlu1 but not mGlu5 receptors appear to be involved in the
mechanisms leading to postischemic neurodegeneration (Pellegrini-
Giampietro, 2003).
In an attempt to understand the underlying mechanisms in the
development of ischemic tolerance, we also examined whether
ischemic or pharmacological preconditioning could alter the
excitotoxic effects of glutamate receptor agonists. We used a range
of concentrations of AMPA and NMDA to induce increasing
excitotoxic responses and we evaluated their effects in control slices
and in slices exposed 24 h earlier to either the ischemic or the
pharmacological preconditioning protocol. Our results indicate that
the excitotoxic potential of AMPA and NMDA receptor agonists
was reduced in preconditioned slices; this is in accord with reports
showing that cortical cultures preconditioned with KCN (McLaugh-
lin et al., 2003) or organotypic hippocampal slices preconditioned
with DHPG (Blaabjerg et al., 2003) are protected against NMDA
excitotoxicity. The reduced NMDA response after preconditioning
stimuli has been associated with caspase 3 activation and increased
production of neuroprotective proteins such as HSP 70 (McLaughlin
et al., 2003) or with Rab5b-stimulated endocytosis of NMDA
receptors (Baskys et al., 2005). Similarly, ischemic preconditioning
confers neuroprotection against global ischemia in vivo by attenu-
ating the postischemic modifications in subunit composition that
lead to the formation of Ca2+-permeable AMPA receptors (Tanaka
et al., 2002).
In a similar manner, ischemic preconditioning significantly
reduced the excitotoxic potential of the group I mGlu receptor
agonist DHPG, as evaluated by applying the compound (which was
not toxic by itself) to slices simultaneously exposed to a mild
(20 min) OGD. As predicted (Gasparini et al., 1999; Pellegrini-
Giampietro et al., 1999a), DHPG significantly exacerbated CA1
injury in control slices while, in slices preconditioned 24 h earlier
with a brief (10 min) OGD, DHPG excitotoxicity was diminished.
Because group I mGlu receptors are known to desensitize depend-
ing on their level of phosphorylation (Dale et al., 2002), it is
possible that ischemic preconditioning may trigger phosphorylation
mechanisms leading to receptor desensitization and hence to
ischemic tolerance. Again, the results of the experiments performed
using mGlu1- and mGlu5-selective antagonists suggest that a loss
of mGlu1 rather than mGlu5 receptor function may be responsible
for the increased tolerance to OGD.
In contrast, a brief exposure of group I mGlu receptors to their
selective agonist DHPG (10 lm), as observed in our pharmacological
preconditioning model, may sensitize mGlu1 and ⁄ or mGlu5 receptors,
thereby activating transient neurotoxic mechanisms. Indeed, in
pharmacologically preconditioned slices, DHPG excitotoxicity in mild
OGD was more than doubled. The enhanced excitotoxic DHPG
response was blocked not by LY367385 but by MPEP, indicating that
it was mGlu1-independent and presumably mediated via mGlu5
receptor activation. Thus, pharmacological preconditioning with
10 lm DHPG may activate processes that sensitize mGlu5 receptors;
the subsequent addition of 100 lm DHPG during mild OGD appears
to unmask their excitotoxic potential. Receptor sensitization may be
a result of the recruitment of mGlu5 receptors previously uncoupled
to their effector G-proteins (receptor reserve). Further studies are
necessary to investigate which intracellular signalling cascades are
involved in mGlu1 or mGlu5 receptor-dependent induction of
ischemic tolerance.
In conclusion, our results show that group I mGlu receptors are
differentially involved in the mechanisms leading to ischemic
tolerance following either ischemic or pharmacological precondi-
tioning. The decreased mGlu1 receptor-induced excitotoxicity in
ischemically preconditioned slices suggests that changes in mGlu1
receptor function following a brief exposure to OGD may be
responsible for the development of ischemic tolerance. The results
in slices preconditioned by a brief pre-exposure to DHPG suggest
that under these circumstances mGlu5 receptors may become
sensitized to subsequently produce an enhanced toxic response to
the receptor agonist.
Fig. 7. Pharmacological preconditioning (PP) enhanced DHPG toxicity in rat
organotypic hippocampal slices. Slices were exposed to 100 lm DHPG, OGD
or DHPG + OGD for 20 min and 48 h later CA1 damage was assessed by
measuring the intensity of PI fluorescence. Data are expressed as percentages of
20 min OGD-induced neuronal death. The toxicity evoked by DHPG was
significantly exacerbated when slices were pre-exposed 24 h earlier to 10 lm
DHPG for 30 min (PP). The mGlu5 receptor antagonist MPEP (10 lm), but not
the mGlu1 receptor antagonist LY367385 (100 lm), was able to prevent the
potentiation of DHPG neurotoxicity induced by PP. Bars represent the
mean ± SEM of n ‡ 4 experiments run in quadruplicate. *P < 0.05 and
**P < 0.01 vs. OGD 20 min alone.
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